Physician profile
Avin Pothuloori
NPI 1245523141
$13,430.42
in general payments reported to CMS, 2019-2025
34 companies · $9,842 in 2025
The $9,842 reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2021: $117 · 2022: $141 · 2023: $611 · 2024: $2,560 · 2025: $9,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,250 · Food and Beverage: $5,697 · Travel and Lodging: $1,034 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,250.00 |
| Food and Beverage | $5,697.02 |
| Travel and Lodging | $1,034.19 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $7,960.07 | 2024-2025 | Mycapssa, Juxtapid, Myalept |
| Beta Bionics, INC. | $889.68 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $705.03 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.92 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $437.97 | 2021-2025 | |
| Lilly USA, LLC | $394.46 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $367.74 | 2024-2025 | Korlym |
| Novo Nordisk INC | $355.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Recordati_rare_diseases_inc. | $278.88 | 2023-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $216.52 | 2023-2025 | |
| Medtronic Minimed, INC. | $159.59 | 2019 | |
| Insulet Corporation | $150.47 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $140.91 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $106.75 | 2022-2025 | Tymlos |
| Convatec INC. | $98.46 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $87.74 | 2024-2025 | |
| Medtronic, INC. | $86.72 | 2023-2025 | Minimed 780g |
| Amgen INC. | $82.23 | 2022-2025 | Tepezza, Prolia, Evenity |
| Ascensia Diabetes Care US INC. | $53.94 | 2023-2025 | |
| Horizon Therapeutics Plc | $53.91 | 2023 | Tepezza |
| Madrigal Pharmaceuticals | $46.46 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $37.64 | 2024-2025 | Crysvita |
| Sequel Med Tech, LLC | $30.81 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $30.54 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $27.52 | 2023 | |
| Averitas Pharma INC. | $22.81 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $20.28 | 2023 | Strensiq |
| Antares Pharma, INC. | $19.61 | 2022 | |
| Abbvie INC. | $18.52 | 2023 | |
| Ascendis Pharma Endocrinology INC | $17.00 | 2025 | Yorvipath |
| Cequr Corporation | $16.62 | 2022 | |
| Tolmar, INC. | $15.73 | 2024 | |
| Amryt Pharma Holdings LTD | $15.42 | 2023 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $14.47 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avin Pothuloori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.